Navigation Links
MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating,MacroVascular Outcomes Presented at the American Diabetes,Association 67th Scientific Sessions

compounds in development for diabetes, cardiovascular disease and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit www.tpna.com.

ACTOS(R) (pioglitazone HCl) is a registered trademark of Takeda Pharmaceutical Company Limited and used under license by Takeda Pharmaceuticals North America, Inc.

North America, Inc.

CONTACT: Jocelyn M. Gerst of Takeda Global Research & Development,+1-224-554-5542, ; or Amy Losak of Ketchum, +1-646-935-3917,cell, +1-917-865-6688, , for Takeda PharmaceuticalsNorth America, Inc. jgerst@tgrd.com amy.losak@ketchum.com

Web site: http://www.tpna.com/http://www.actos.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
2. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
3. Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis
4. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
5. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
6. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
7. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
10. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
11. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
Post Your Comments:
Breaking Medicine Technology:Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 1PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 2PROSTVAC 28TM 29 Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late Stage Prostate Can 12379 3Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 1Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 2Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 3Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study 12376 4Back to normal 3A Surgery improves outcomes for spine patients 47438 1Back to normal 3A Surgery improves outcomes for spine patients 47438 2